Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics

被引:52
作者
Bon, C. [1 ]
Toutain, P. L. [2 ]
Concordet, D. [3 ,4 ,5 ]
Gehring, R. [6 ]
Martin-Jimenez, T. [7 ]
Smith, J. [8 ]
Pelligand, L. [2 ]
Martinez, M. [9 ]
Whittem, T. [10 ]
Riviere, J. E. [6 ]
Mochel, J. P. [11 ]
机构
[1] Roche Innovat Ctr, Roche Pharmaceut Res & Early Dev, Basel, Switzerland
[2] Royal Vet Coll, Dept Vet Basic Sci, Hatfield, Herts, England
[3] INRA, Toxalim, Res Ctr Food Toxicol, Toulouse, France
[4] Univ Toulouse, ENVT, INP, Toxalim, Toulouse, France
[5] Ecole Natl Vet Toulouse, INRA, Lab Physiol & Therapeut, UMR 1331, Toulouse, France
[6] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Inst Computat Comparat Med ICCM, Manhattan, KS 66506 USA
[7] Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN USA
[8] Iowa State Univ, Vet Diagnost & Prod Anim Med, Coll Vet Med, Ames, IA USA
[9] US FDA, Ctr Vet Med, Rockville, MD 20857 USA
[10] Univ Melbourne, Translat Res & Anim Clin Trials TRACTs Grp, Fac Vet & Agr Sci, Werribee, Vic, Australia
[11] Iowa State Univ, Biomed Sci, Coll Vet Med, Ames, IA 50011 USA
关键词
covariates; nonlinear mixed effects; population pharmacokinetics; sparse sampling; veterinary medicine; EFFICIENT PARAMETER-ESTIMATION; POPULATION PHARMACOKINETICS; BLOOD-PRESSURE; VETERINARY-MEDICINE; SAMPLING STRATEGIES; EXPERIMENTAL-DESIGN; FLUNIXIN MEGLUMINE; HANDLING DATA; DOGS; QUANTIFICATION;
D O I
10.1111/jvp.12473
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A common feature of human and veterinary pharmacokinetics is the importance of identifying and quantifying the key determinants of between-patient variability in drug disposition and effects. Some of these attributes are already well known to the field of human pharmacology such as bodyweight, age, or sex, while others are more specific to veterinary medicine, such as species, breed, and social behavior. Identification of these attributes has the potential to allow a better and more tailored use of therapeutic drugs both in companion and food-producing animals. Nonlinear mixed effects (NLME) have been purposely designed to characterize the sources of variability in drug disposition and response. The NLME approach can be used to explore the impact of population-associated variables on the relationship between drug administration, systemic exposure, and the levels of drug residues in tissues. The latter, while different from the method used by the US Food and Drug Administration for setting official withdrawal times (WT) can also be beneficial for estimating WT of approved animal drug products when used in an extralabel manner. Finally, NLME can also prove useful to optimize dosing schedules, or to analyze sparse data collected in situations where intensive blood collection is technically challenging, as in small animal species presenting limited blood volume such as poultry and fish.
引用
收藏
页码:171 / 183
页数:13
相关论文
共 81 条
  • [1] Likelihood based approaches to handling data below the quantification limit using NONMEM VI
    Ahn, Jae Eun
    Karlsson, Mats O.
    Dunne, Adrian
    Ludden, Thomas M.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2008, 35 (04) : 401 - 421
  • [2] EXPERIMENTAL-DESIGN AND EFFICIENT PARAMETER-ESTIMATION IN POPULATION PHARMACOKINETICS
    ALBANNA, MK
    KELMAN, AW
    WHITING, B
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (04): : 347 - 360
  • [3] Ways to fit a PK model with some data below the quantification limit
    Beal, SL
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) : 481 - 504
  • [4] Handling Data Below the Limit of Quantification in Mixed Effect Models
    Bergstrand, Martin
    Karlsson, Mats O.
    [J]. AAPS JOURNAL, 2009, 11 (02): : 371 - 380
  • [5] Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P583, DOI 10.1007/978-1-4419-9485-1
  • [6] The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data
    Chevance, A.
    Jacques, A. -M.
    Laurentie, M.
    Sanders, P.
    Henri, J.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2017, 40 (03) : 218 - 230
  • [7] Population pharmacokinetics of mavacoxib in osteoarthritic dogs
    Cox, S. R.
    Liao, S.
    Payne-Johnson, M.
    Zielinski, R. J.
    Stegemann, M. R.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2011, 34 (01) : 1 - 11
  • [8] Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
    Desai, Amit
    Kovanda, Laura
    Kowalski, Donna
    Lu, Qiaoyang
    Townsend, Robert
    Bonate, Peter L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5483 - 5491
  • [9] AN EVALUATION OF OPTIMAL SAMPLING STRATEGY AND ADAPTIVE STUDY DESIGN
    DRUSANO, GL
    FORREST, A
    SNYDER, MJ
    REED, MD
    BLUMER, JL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) : 232 - 238
  • [10] ENDRENYI L, 1981, DESIGN ANAL ENZYME P, P137